NCT04470674 is a Phase 2 clinical trial of Durvalumab in Lung Cancer, sponsored by Shirish M Gadgeel.

Who is sponsoring NCT04470674?

NCT04470674 is sponsored by Shirish M Gadgeel.

What drugs are being tested in NCT04470674?

Interventions in NCT04470674: Durvalumab, Carboplatin, Pemetrexed.

What condition does NCT04470674 study?

NCT04470674 studies Lung Cancer, Non-small Cell Lung Cancer, PD-L1 Gene Mutation, KRAS Activating Mutation.

Is NCT04470674 still recruiting?

NCT04470674 is currently withdrawn. Last updated 3 March 2022.

Last reviewed 2022-03-03 · How we verify

NCT04470674

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients

Withdrawn Phase 2 Last updated 3 March 2022

What this trial tests

Phase 2 trial testing Durvalumab in Lung Cancer. Withdrawn.

Timeline

6 April 2021

Primary endpoint
8 June 2021

8 June 2021

Quick facts

Lead sponsor	Shirish M Gadgeel
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	6 April 2021
Primary completion	8 June 2021
Estimated completion	8 June 2021
Sites	1 location across United States

Drugs / interventions tested

Durvalumab — full drug profile →
Carboplatin (Carboplatin) — full drug profile →
Pemetrexed — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →
Non-small Cell Lung Cancer — all drugs for Non-small Cell Lung Cancer →
PD-L1 Gene Mutation — all drugs for PD-L1 Gene Mutation →
KRAS Activating Mutation — all drugs for KRAS Activating Mutation →

Sponsor

Shirish M Gadgeel

Who can join

18 and older, any sex, with Lung Cancer or Non-small Cell Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a two arm, randomized, phase II study of patients with advanced KRAS mutation positive and PD-L1 high NSCLC who have not received therapy for advanced stage disease. Patients will be randomized between Arm A and Arm B treatment. Arm A treatment will consist of durvalumab every 4 weeks for 13 cycles. Arm B treatment will consist of durvalumab with chemotherapy every 3 weeks for 4 cycles followed by durvalumab with pemetrexed every 3 weeks for 13 cycles.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Development of synthetic lethality in cancer: molecular and cellular classification.
Li S, Topatana W, Juengpanich S, Cao J, et al · · 2020 · cited 82× · PMID 33077733 · DOI 10.1038/s41392-020-00358-6
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup.
Xie M, Xu X, Fan Y. · · 2021 · cited 46× · PMID 34012925 · DOI 10.3389/fonc.2021.672612
Targeting KRAS in NSCLC: Old Failures and New Options for "Non-G12c" Patients.
Jacobs F, Cani M, Malapelle U, Novello S, et al · · 2021 · cited 14× · PMID 34944952 · DOI 10.3390/cancers13246332
[Application Progress of Immune Checkpoint Inhibitors  in Oncogene-driven Advanced Non-small Cell Lung Cancer].
Zhang T, Li B. · · 2021 · cited 1× · PMID 33819969 · DOI 10.3779/j.issn.1009-3419.2021.101.04

Verify or expand the search:

Other trials of Durvalumab

Trials testing the same drug.

NCT07507968 — TNT With FLOT/Durvalumab Plus Post-OP Durvalumab for Resectable Gastroesophageal Adenocarcinoma · Phase 2 · not yet recruiting
NCT07332351 — Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle · Phase 2 · not yet recruiting
NCT07339059 — Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Ce · Phase 2 · recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT07459634 — A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC · Phase 2 · not yet recruiting

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04470674 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shirish M Gadgeel
Last refreshed: 3 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04470674.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing